Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial
NewsAug 31, 2026
- Markets
- MasterclassNEW
- Portfolio X-rayNEW
- My Watchlist
- News
- Stock Recos
- Screeners
- ETMarkets GPTNEW
US StocksNEW
- Sector: Pharmaceuticals
- Industry: Pharma - Indian
Cadila Healthcare - Zydus Lifesciences Share Price
1,119.101.30 (0.12%)
Volume: 10,38,792
ClosedLast Updated On: 11 Sep, 2026, 03:54 PM IST
- High:--
- Low:--
- Returns:--
Loading...
Research insights
Stock Recommendations
Potential
Upside*1 Year
Target
HOLD
Mean Recos by
29 Analysts
Stock Reports Plus
/10
Stock Score
View Report
| Earnings | |
| Fundamentals | |
| Relative Valuation | |
| Risk | |
| Price Momentum |
No Rating (NR)
Negative
Neutral
Positive
* Investments in securities are subject to market risks. These are indicative and should not be interpreted as investment advice or guaranteed returns.
Key Metrics
PE RatioThis is a ratio arrived at by dividing the current market price of a stock by its latest (annual or annualized) earnings per share. Here we have taken the TTM (trailing twelve months) adjusted earnings per share. | 24.74 | ||||||||||
EPS - TTMEarnings per share (TTM) tells the profit after tax earned on a per share basis by a stock over the last twelve months or four quarters. | 45.24 | ||||||||||
MCapMCap or Market capitalization of a stock is calculated by multiplying the total number of shares outstanding of that particular stock with its current market price. | 1,11,630.65 | ||||||||||
Sectoral MCap RankThis is the ranking of a company within its sector based on MCap or Market capitalization. Higher the market capitalization of a company, higher the rank it is assigned. | 4 | ||||||||||
PB RatioPrice to Book represents the ratio of current market price of a stock to its book value per share. The book value itself is arrived at by dividing the net worth of a company by the total number of shares outstanding of the company at that time. | 3.77 | ||||||||||
Dividend YieldDividend Yield calculates the amount of full year dividend declared by a company as a percentage of the current market price of a stock. All other things being equal, higher the dividend yield of the stock, the better it is for investors. | 0.09 | ||||||||||
Face ValueFace value of a stock is the value ascribed to the stock as per the balance sheet of the company. The dividend declared by a company is usually declared as a percentage of face value. | 1.00 | ||||||||||
Beta
| 1.50 | ||||||||||
VWAPVolume Weighted Average Price represents the average price of a security over a particular time period (example one trading day) weighted by the volume traded at each price point. | 1,122.59 | ||||||||||
52W H/LThis represents the 52 week high and low price of the security. It is also the 1 year high and low of the security. This represents the highest and lowest price touched by the security during the past 52 weeks or 1 year including today. | 1,205.00 / 835.50 |
Cadila Healthcare Share Price Insights
- Company has spent 1.62% of its operating revenues towards interest expenses and 16.27% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
- Weekly MACD crossover appeared on week ending Sep 11, 2026. Average price decline of -5.19% within 7 weeks of this signal in last 10 years.
- Company has used Rs 8296.1 cr for investing activities which is an YoY decrease of 0.91%. (Source: Consolidated Financials)
Zydus Lifesciences Ltd. share price moved up by 0.12% from its previous close of Rs 1,117.80. Zydus Lifesciences Ltd. stock last traded price is 1,119.10
Share Price Value Today/Current/Last 1,119.10 Previous Day 1,117.80
Cadila Healthcare Share Price Returns
| 1 Day | 0.12% |
| 1 Week | -0.08% |
| 1 Month | -6.04% |
| 3 Months | 1.19% |
| 1 Year | 7.23% |
| 3 Years | 78.04% |
| 5 Years | 100.52% |
ET Stock ScreenersTop Score Companies
Check whether Cadila Healthcare belongs to analysts' top-rated companies list?
View Stock ScreenersNews & Analysis
Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial
Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection
NewsAug 21, 2026
Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target
NewsAug 12, 2026
Announcement under Regulation 30 (LODR)-Credit Rating
Share Recommendations
Recent Recos
Current
Mean Recos by 29 Analysts
HOLD
Strong SellSellHoldBuyStrong Buy
Analyst Trends
| Ratings | Current | 1 Week Ago | 1 Month Ago | 3 Months Ago |
|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 |
| Buy | 11 | 11 | 11 | 9 |
| Hold | 7 | 7 | 7 | 10 |
| Sell | 5 | 5 | 5 | 3 |
| Strong Sell | 2 | 2 | 2 | 2 |
| # Analysts | 29 | 29 | 30 | 30 |
Financials
Insights
| | JUN 2026 | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 |
|---|---|---|---|---|---|
| Total Income | 8,123.10 | 7,721.20 | 6,975.90 | 6,232.20 | 6,728.60 |
| Total Income Growth (%) | 5.21 | 10.68 | 11.93 | -7.38 | 1.82 |
| Total Expenses | 6,660.50 | 5,938.50 | 5,492.60 | 4,443.50 | 4,723.30 |
| Total Expenses Growth (%) | 12.16 | 8.12 | 23.61 | -5.92 | -2.81 |
| EBIT | 1,462.60 | 1,782.70 | 1,483.30 | 1,788.70 | 2,005.30 |
| EBIT Growth (%) | -17.96 | 20.18 | -17.07 | -10.80 | 14.68 |
| Profit after Tax (PAT) | 939.80 | 1,272.50 | 1,042.10 | 1,258.60 | 1,466.80 |
| PAT Growth (%) | -26.15 | 22.11 | -17.20 | -14.19 | 25.27 |
| EBIT Margin (%) | 18.01 | 23.09 | 21.26 | 28.70 | 29.80 |
| Net Profit Margin (%) | 11.57 | 16.48 | 14.94 | 20.20 | 21.80 |
| Basic EPS () | 9.35 | 12.65 | 10.36 | 12.51 | 14.58 |
All figures in Rs Cr, unless mentioned otherwise
View DetailsShare Price Forecast
Get multiple analysts' prediction on Cadila Healthcare
- High, low, medium predictions for Price
- Upcoming predictions for Revenue
- Details about company earnings
Technicals
Peer Comparison
MF Ownership
2,170.53
Amount Invested (in Cr.)
1.46233582%
% of AUM
0.00
% Change (MoM basis)
1,173.18
Amount Invested (in Cr.)
2.09%
% of AUM
0.00
% Change (MoM basis)
315.87
Amount Invested (in Cr.)
0.39015645%
% of AUM
0.00
% Change (MoM basis)
Cadila Healthcare F&O Quote
- Expiry
Price
1,124.90-2.40 (-0.21%)
Open Interest
1,13,33,70068,400 (0.61%)
| Open | High | Low | Prev Close | Contracts Traded | Turnover (₹ Lakhs) |
|---|---|---|---|---|---|
| 1,110.30 | 1,139.90 | 1,110.00 | 1,127.30 | 1,636 | 16,558.96 |
Open Interest as of 11 Sept 2026
Corporate Actions
| Meeting Date | Announced on | Purpose | Details |
|---|---|---|---|
| Aug 11, 2026 | Jul 20, 2026 | Board Meeting | Quarterly Results |
| Aug 11, 2026 | May 20, 2026 | AGM | General Meeting |
| May 19, 2026 | May 13, 2026 | Board Meeting | Audited Results, Dividend & Buy Back |
| Feb 9, 2026 | Jan 27, 2026 | Board Meeting | Quarterly Results |
| Nov 6, 2025 | Nov 3, 2025 | Board Meeting | Quarterly Results & Fund raising |
| Aug 12, 2025 | Aug 1, 2025 | Board Meeting | Quarterly Results |
| - | May 19, 2026 | Others | Buy Back of Shares |
About Cadila Healthcare
Zydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 1,11,630.65 Crore) operating in Pharmaceuticals sector.
Zydus Lifesciences Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2026.
PP
Pankaj R Patel
ChairmanSP
Sharvil P Patel
Managing DirectorGN
Ganesh N Nayak
Executive DirectorMP
Mukesh M Patel
Non Executive DirectorIndustry
Key Indices Listed On
Nifty Next 50, Nifty 100, Nifty 200, + 30 more
Address
Zydus Corporate Park, Scheme No.63,, Survey No. 536,, Khoraj (Gandhinagar),, Ahmedabad, Gujarat, 382481
More Details
FAQs about Cadila Healthcare share
- 1. What's the Cadila Healthcare share price today?Cadila Healthcare share price is Rs 1,119.10 as on 11 Sep, 2026, 03:54 PM IST. Cadila Healthcare share price is up by 0.12% based on previous share price of Rs. 1127.4.
- 2. What is Cadila Healthcare's 52 week high / low?52 Week high of Cadila Healthcare share is Rs 1,205.00 while 52 week low is Rs 835.50
- 3. What is the market cap of Cadila Healthcare?Within the Pharmaceuticals sector, Cadila Healthcare stock has a market cap rank of 4. Cadila Healthcare has a market cap of Rs 111,631 Cr.
- 4. What are the returns for Cadila Healthcare share?Return Performance of Cadila Healthcare Shares: 1 Week: Cadila Healthcare share price moved down by 0.08%
- 5. What is the PE & PB ratio of Cadila Healthcare?The PE ratio of Cadila Healthcare stands at 24.71, while the PB ratio is 3.8.
Trending in Markets
Top Gainers
Top Losers
Cadila Healthcare Quick Links
Equity Quick Links
More from Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.
